Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Rong FanHatice SatilmisNiels VandewalleEmma VerheyePhilip VlummensAnke MaesCatharina MuylaertElke De BruyneEline MenuHolly EvansAndrew ChantryNathan De BeuleDirk HoseMarie TörngrenHelena ErikssonKarin VanderkerkenKen MaesKarine BreckpotKim De VeirmanPublished in: Journal for immunotherapy of cancer (2023)
Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.
Keyphrases
- combination therapy
- end stage renal disease
- multiple myeloma
- signaling pathway
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- poor prognosis
- peritoneal dialysis
- acute myeloid leukemia
- dendritic cells
- bone mineral density
- immune response
- cell death
- endoplasmic reticulum stress
- cell proliferation
- soft tissue
- body composition
- binding protein